Abstract:
A traditional Chinese medicine composition for treating hand-foot syndrome after targeted drug treatment is mainly prepared from the following components by weight: 20-50 parts of Radix Sophorae Flavescentis, 20-50 parts of Herba Taraxaci, 20-50 parts of Flos Chrysanthemi Indici, and 20-50 parts of Herba Cum Radice Violae Yedoensitis, 20-50 parts of Rhizoma Smilacis Glabrae, 30-60 parts of Radix Astragali Seu Hedysari, 10-35 parts of Kochia scoparia (L.) Schrad, 10-45 parts of Carthamus tinctorius L., 15-45 parts of Cortex Radicis Dictamni Dasycarpi, 5-15 parts of Herba Ephedrae, 5-25 parts of Angelica sinensis, 5-25 parts of Rhizoma Ligustici Chuangxiong, 10-30 parts of Radix Rehmanniae, 5-15 parts of Ramulus cinnamomi, 10-30 parts of Cynanchum otophyllum Schneid, 5-15 parts of Semen Sinapis Albae, 5-20 parts of Arisaema heterophyllum Blume, 5-20 parts of Typhonium blumei Nicolson & Sivadasan, and 10-40 parts of Radix Glycyrrhizae.
Abstract:
The present disclosure provides a use of pentosan polysulfate sodium (PPS) in the manufacture of a medicament for the prevention of recurrent urinary tract infection (rUTI) in a human subject, comprising a therapeutically effective dosage for oral administration of PPS, wherein the therapeutically effective dosage for oral administration of PPS is 5-1 mg/kg/day.
Abstract:
The invention relates to a preparation method of new-type nanoparticles for loading emodin, which comprises: using L.A, mPEG and stannous iso caprylate to synthesize a first intermediate product; using the first intermediate product, butanedioic anhydride and 4-dimethylaminopyridine to synthesize a second intermediate product; using the second intermediate product, 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride, N-hydroxysuccinimide and chitosan to synthesize a third intermediate product; using the third intermediate product and sodium periodate to synthesize a fourth intermediate product; using the fourth intermediate product and 5-amino-2-mercapto benzimidazole to synthesize the new-type thiolated nanoparticles. The nanoparticles loaded with emodin are used for intestinal tract dose, which may enhance the nanoparticles' adhesion ability, prolong residence time of drugs on mucosal membranes, and facilitate sustained-release of drug molecules. The encapsulation efficiency after loading drugs is no less than 83.6%, the drug loading capacity is no less than 3.89%, and good water solubility and biological degradability are provided.
Abstract:
A cell smearing apparatus comprising: a mixed solution container accommodation unit accommodating a mixed solution container containing a mixed solution of cells and a preservation solution; a suction unit suctioning the mixed solution from the mixed solution container accommodated in the mixed solution container accommodation unit; a sensor unit sensing variation of the mixed solution suctioned by the suction unit; and a controller controlling a suctioning speed of the suction unit based on a value sensed by the sensor unit. The present invention allows cells to be examined to be smeared as a monolayer on a slide for microscopic examination.
Abstract:
Composition and methods using the compositions are disclosed, where the compositions include heterocyclic aromatic amines, substituted heterocyclic aromatic amines, poly vinyl heterocyclic aromatic amines, co-polymers of vinyl heterocyclic aromatic amine and non amine polymerizable monomers (ethylenically unsaturated mononers and diene monomers), or mixtures or combinations thereof reacted with sulfonic acids, alkyl sulfonic acids, sulfosuccinates, sulfamic acids, sulfuric acids or partially neutralized amine or other alkali sulfonate and/or reacted with alpha hydroxyl carboxcylic acids which form coatings that alter self-aggregating properties and/or aggregation propensities of the particles and surfaces. Furthermore, the coating can be used to improve filtration of fluids through particulate matter and it is found that the coating will increase hydrocarbon liquid and gas flow through or over treated particulates and surfaces.
Abstract:
The present invention provides a pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease, comprising 50 to 90% by weight of Cordyceps sinensis mycelium powder, and 10 to 50% by weight of condensed astragalus powder.
Abstract:
The present invention provides a pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease, comprising 50 to 90% by weight of Cordyceps sinensis mycelium powder, and 10 to 50% by weight of condensed astragalus powder.